Lantheus wins FDA approval for PYLARIFY TruVu, increases PSMA PET capacity

Lantheus Holdings said the U.S. Food and Drug Administration approved PYLARIFY TruVu (piflufolastat F 18), a new formulation of its F-18 prostate-specific membrane antigen PET imaging agent designed to increase production capacity and widen distribution. The company expects commercial availability in the fourth quarter of 2026 with a phased, geographic rollout to allow customers to transition from the current PYLARIFY product with minimal disruption.

The approval covers PET imaging of PSMA-positive lesions in men with prostate cancer who have suspected metastasis and those with suspected recurrence based on elevated PSA. Lantheus filed the application under the 505(b)(2) regulatory pathway, which permitted the agency to review previously submitted data from the pivotal OSPREY and CONDOR studies supporting the original PYLARIFY approvals.

Company materials describe TruVu as retaining the diagnostic performance of PYLARIFY while being built to handle higher radioactive concentrations, improving stability for larger batch production and more efficient distribution. The move is expected to increase batch size by about 50%, a change that company filings and market commentary say should improve margins and help suppliers reach geographic areas where clinics do not yet have access to PSMA PET scans.

Mary Anne Heino, Lantheus’ Executive Chairperson and Chief Executive Officer, framed the approval as an access milestone: "The FDA approval of PYLARIFY TruVu demonstrates Lantheus’ continued commitment to advancing innovation that directly expands patient access to high-quality diagnostic tools." She added, "The availability of PYLARIFY TruVu addresses a key need identified by clinicians – greater access to our market-leading formulation."

A PSMA PET scan uses a small dose of radioactive material that binds to prostate cancer cells, helping doctors detect even tiny signs that the cancer has returned or spread. Clinicians and health systems have increasingly cited limited local availability of PSMA imaging as a barrier to timely diagnosis and treatment planning, particularly for patients outside major metropolitan centers.

The approval has drawn positive investor reaction and market commentary that the approval could help re-accelerate company revenue. "The approval is an 'important catalyst' that raises the analysts' confidence in a revenue and profit re-acceleration beginning in the second half of 2026," said Truist analyst Richard Newitter. Shares of Lantheus rose about 4 percent in extended trading after the announcement.

Public health implications hinge on whether larger batch production translates into meaningful increases in scans performed, especially in underserved communities. The company’s description positions TruVu to expand geographic reach, which could shorten travel for patients seeking high-precision imaging and speed decisions about surgery, radiation and systemic therapy. However, the press materials do not provide pricing, reimbursement details or post-approval study commitments, all of which will shape who benefits from expanded supply.

Lantheus described the rollout as staged across regions to ensure a seamless transition for existing customers and suppliers. The approval, and the technical change to enable higher-radioactivity batches, addresses a supply-side bottleneck in nuclear medicine capacity. Whether that technical gain reduces disparities in access will depend on follow-up by payers, hospital networks and public health programs to ensure scans reach patients in community settings as well as academic centers.